Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on developing innovative therapies for retinal diseases and other eye conditions, has announced its plans to host a conference call and webcast on August 7, 2024, at 8:00 AM ET. The event will cover recent business progress and financial results for the second quarter ended June 30, 2024.
Participants can join the call using the following details:
- U.S. Dial-In: 1 (800) 343-4136
- International Dial-in: 1 (203) 518-9843
- Conference ID: OCULAR
Ocular Therapeutix (NASDAQ:OCUL), un'azienda biofarmaceutica concentrata sullo sviluppo di terapie innovative per malattie retiniche e altre condizioni oculari, ha annunciato i suoi piani per ospitare una conferenza telefonica e un webcast il 7 agosto 2024, alle 8:00 AM ET. L'evento tratterà dei recenti progressi aziendali e dei risultati finanziari per il secondo trimestre conclusosi il 30 giugno 2024.
I partecipanti possono unirsi alla chiamata utilizzando i seguenti dettagli:
- Numero per gli Stati Uniti: 1 (800) 343-4136
- Numero internazionale: 1 (203) 518-9843
- ID della conferenza: OCULAR
Ocular Therapeutix (NASDAQ:OCUL), una empresa biofarmacéutica enfocada en desarrollar terapias innovadoras para enfermedades de la retina y otras condiciones oculares, ha anunciado sus planes para realizar una conferencia telefónica y un webcast el 7 de agosto de 2024, a las 8:00 AM ET. El evento cubrirá el progreso empresarial reciente y los resultados financieros del segundo trimestre terminado el 30 de junio de 2024.
Los participantes pueden unirse a la llamada utilizando los siguientes detalles:
- Dial-in de EE.UU.: 1 (800) 343-4136
- Dial-in internacional: 1 (203) 518-9843
- ID de la conferencia: OCULAR
Ocular Therapeutix (NASDAQ:OCUL)는 망막 질환 및 기타 안과 질환을 위한 혁신적인 치료제를 개발하는 데 주력하는 생명공학 회사로, 2024년 8월 7일 오전 8시 ET에 컨퍼런스 콜 및 웹캐스트를 개최할 계획을 발표했습니다. 본 행사에서는 2024년 6월 30일로 종료된 두 번째 분기에 대한 최근 사업 진행 상황과 재무 결과를 다룰 것입니다.
참여자는 다음 정보를 사용하여 전화를 받을 수 있습니다:
- 미국 전화번호: 1 (800) 343-4136
- 국제 전화번호: 1 (203) 518-9843
- 컨퍼런스 ID: OCULAR
Ocular Therapeutix (NASDAQ:OCUL), une entreprise biopharmaceutique axée sur le développement de thérapies innovantes pour les maladies rétiniennes et d'autres affections oculaires, a annoncé ses projets d'organiser une conférence téléphonique et un webcast le 7 août 2024, à 8h00 ET. L'événement couvrira les récents progrès de l'entreprise et les résultats financiers du deuxième trimestre se terminant le 30 juin 2024.
Les participants peuvent rejoindre l'appel en utilisant les détails suivants :
- Numéro de composition des États-Unis : 1 (800) 343-4136
- Numéro de composition international : 1 (203) 518-9843
- ID de la conférence : OCULAR
Ocular Therapeutix (NASDAQ:OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien für Netzhauterkrankungen und andere Augenleiden konzentriert, hat seine Pläne bekannt gegeben, am 7. August 2024, um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abzuhalten. Die Veranstaltung wird die jüngsten Fortschritte im Geschäftsbereich sowie die finanziellen Ergebnisse für das zweite Quartal zum 30. Juni 2024 behandeln.
Teilnehmer können über die folgenden Informationen an dem Anruf teilnehmen:
- USA-Telefonnummer: 1 (800) 343-4136
- Internationale Telefonnummer: 1 (203) 518-9843
- Konferenz-ID: OCULAR
- None.
- None.
Conference call and webcast to begin at 8:00 AM ET
BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.
Conference Call and Webcast Information:
Date: Wednesday, August 7, 2024, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (800) 343-4136
Participant Dial-in (International): 1 (203) 518-9843
Conference ID: OCULAR
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When will Ocular Therapeutix (OCUL) report its Q2 2024 financial results?
How can investors access Ocular Therapeutix's (OCUL) Q2 2024 earnings call?
What period will Ocular Therapeutix's (OCUL) Q2 2024 financial results cover?
How long will the webcast replay of Ocular Therapeutix's (OCUL) Q2 2024 earnings call be available?
